Two FDA-Cleared PLAC® Tests

As pioneers in the testing of Lp-PLA2, a validated marker of cardiovascular risk, we have a portfolio of commercially-available PLAC® Tests, the only two FDA-cleared tests to measure Lp-PLA2.

Capabilities and Product Portfolio for Growth

Our extensive capabilities, from development to commercialization, enable our evolution into a multi-product company delivering actionable information to healthcare providers for patient management.

Recent News

November 10, 2015

Diadexus, Inc. Presents New PLAC Activity Data from the REGARDS Study at 2015 American Heart Association Scientific Sessions

October 26, 2015

Diadexus, Inc. Report Third Quarter 2015 Financial Results